Related Experiment Video
Updated: May 21, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
Intravenous pamidronate for refractory lymphedema
A A Beigi1, A M Sadeghi, H Masoudpour
1Department of Vascular Surgery, Isfahan University of Medical Sciences, Alzahra Hospital, Isfahan, Iran.
Background:
Based on beneficial reports of pamidronate use for reflex sympathetic dystrophy in reduction of pain and swelling, this drug can be studied as a novel treatment for refractory lymphedema. This study aims to determine the effectiveness of pamidronate on lymphedema and its possible side effects.
Methods:
Twelve cases of lower limb refractory lymphedema were enrolled. They received intravenous pamidronate monthly for 3 consecutive months and were followed by measuring any discomfort with visual analog scale (VAS) and physician global assessment, based on objective signs of limb volume and circumference.
Results:
The limb volume, circumference, and satisfaction of the patients improved significantly.
Conclusion:
Pamidronate when is added to conservative treatments may reduce lymphedema and improve the patient's comfort.
Related Concept Videos
Pulmonary Embolism III: Nursing Management
Peripheral Artery Disease IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Treatment Resistant Cancers
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis IV: Nursing Management